Phase 2a Exploratory, Randomized, Double-blind, Parallel-group Study of ONO-8577 Compared to Combination of Solifenacin Succinate/ Mirabegron for Overactive Bladder

Trial Profile

Phase 2a Exploratory, Randomized, Double-blind, Parallel-group Study of ONO-8577 Compared to Combination of Solifenacin Succinate/ Mirabegron for Overactive Bladder

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs ONO 8577 (Primary) ; Mirabegron; Solifenacin
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 25 Sep 2017 Planned End Date changed from 1 Mar 2018 to 1 Oct 2017.
    • 25 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 13 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top